Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study by Mocking, RJT et al.
Vulnerability for new episodes in
recurrent major depressive disorder:
protocol for the longitudinal
DELTA-neuroimaging cohort study
Roel J T Mocking,1 Caroline A Figueroa,1 Maria M Rive,1 Hanneke Geugies,2,3
Michelle N Servaas,2,3 Johanna Assies,1 Maarten W J Koeter,1 Frédéric M Vaz,4
Marieke Wichers,5 Jan P van Straalen,6 Rudi de Raedt,7 Claudi L H Bockting,8,9
Catherine J Harmer,10 Aart H Schene,1,11,12 Henricus G Ruhé1,2,3,5
To cite: Mocking RJT,
Figueroa CA, Rive MM, et al.
Vulnerability for new
episodes in recurrent major
depressive disorder: protocol
for the longitudinal
DELTA-neuroimaging cohort
study. BMJ Open 2016;6:
e009510. doi:10.1136/
bmjopen-2015-009510
▸ Prepublication history
and additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
009510).
Received 24 July 2015
Revised 20 November 2015
Accepted 6 January 2016
For numbered affiliations see
end of article.
Correspondence to
Roel J T Mocking;
R.J.Mocking@AMC.UvA.nl
ABSTRACT
Introduction: Major depressive disorder (MDD) is
widely prevalent and severely disabling, mainly due to
its recurrent nature. A better understanding of the
mechanisms underlying MDD-recurrence may help to
identify high-risk patients and to improve the
preventive treatment they need. MDD-recurrence has
been considered from various levels of perspective
including symptomatology, affective neuropsychology,
brain circuitry and endocrinology/metabolism.
However, MDD-recurrence understanding is limited,
because these perspectives have been studied mainly
in isolation, cross-sectionally in depressed patients.
Therefore, we aim at improving MDD-recurrence
understanding by studying these four selected
perspectives in combination and prospectively during
remission.
Methods and analysis: In a cohort design, we will
include 60 remitted, unipolar, unmedicated, recurrent
MDD-participants (35–65 years) with ≥2 MDD-
episodes. At baseline, we will compare the MDD-
participants with 40 matched controls. Subsequently,
we will follow-up the MDD-participants for 2.5 years
while monitoring recurrences. We will invite
participants with a recurrence to repeat baseline
measurements, together with matched remitted MDD-
participants. Measurements include questionnaires, sad
mood-induction, lifestyle/diet, 3 T structural (T1-
weighted and diffusion tensor imaging) and blood-
oxygen-level-dependent functional MRI (fMRI) and
MR-spectroscopy. fMRI focusses on resting state,
reward/aversive-related learning and emotion
regulation. With affective neuropsychological tasks we
will test emotional processing. Moreover, we will
assess endocrinology (salivary hypothalamic-pituitary-
adrenal-axis cortisol and dehydroepiandrosterone-
sulfate) and metabolism (metabolomics including
polyunsaturated fatty acids), and store blood for, for
example, inflammation analyses, genomics and
proteomics. Finally, we will perform repeated
momentary daily assessments using experience
sampling methods at baseline. We will integrate
measures to test: (1) differences between
MDD-participants and controls; (2) associations of
baseline measures with retro/prospective recurrence-
rates; and (3) repeated measures changes during
follow-up recurrence. This data set will allow us to
study different predictors of recurrence in combination.
Ethics and dissemination: The local ethics
committee approved this study (AMC-METC-Nr.:11/
050). We will submit results for publication in peer-
reviewed journals and presentation at (inter)national
scientific meetings.
Trial registration number: NTR3768.
INTRODUCTION
Rationale
Major depressive disorder (MDD) is a wide-
spread and disabling mental disorder, with
Strengths and limitations of this study
▪ Strict and specific inclusion-criteria, matching-
procedure and recruitment-procedure, leading to
maximal contrast for major depressive disorder
(MDD)-vulnerability, without distortion due to
important confounders: MDD-residual symptoms
and medication.
▪ Unique integration of a wide range of measures
in a prospective repeated measures design will
allow disentangling of recurrent MDD state-
factors and trait-factors.
▪ The extensive assessment procedure needed to
measure all variables of interest and confounders
will potentially lead to inclusion of participants
that are intrinsically aware of the necessity to
perform clinical research and readily willing to
cooperate.
▪ Only including participants who currently do not
use psychotropic drugs may lead to selection of
particular patient subgroups that for example,
previously experienced little benefit or adverse
effects from medication.
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estimated worldwide prevalences of 4.3% annually and
11.1–14.6% during lifetime.1–4 Currently, MDD has the
highest burden of any disorder in high-income coun-
tries, and is expected to have the second-highest burden
worldwide in 2030.5 MDD’s (in)direct annual excess
costs constitute approximately 1% of the gross domestic
product in these countries.6–8 Next to suicide and car-
diovascular comorbidity,9 an important reason for
MDD’s burden is its recurrent course,2 as already indi-
cated by Kraepelin et al10 and formulated by Angst
et al:11 ‘Single episodes are extremely rare if the period
of observation is signiﬁcantly extended’.
The incidence of recurrencesi varies depending on
study-characteristics.12–15 While recurrent MDD has
been considered as a distinct disease entity (more famil-
iar to bipolar disorder), population studies show that
recurrence is widespread in MDD with ≥40–75% life-
time recurrence in patients recovered from a ﬁrst
depressive episode,16–19 with even higher rates in clinical
samples.20 21 Our 10-year follow-up study of a speciﬁc
cohort of recurrent MDD-patients showed an overall
90.3% recurrence-rate,22 with patients being in a
depressed state during 13% of the follow-up time.
During lifetime, MDD-patients are estimated to experi-
ence on average about ﬁve MDD-episodes.1 21
Therefore, high recurrence rates pose a major health
problem. However, depressive episodes seem to cluster
in subpopulations. This also suggests that the most
MDD-episodes occur in a relatively limited number of
patients. Consequently, if we could lower recurrence
rates in these recurring cases, we may greatly reduce the
overall number of MDD-episodes and thereby MDD’s
burden.23 If we could a-priori identify these patients at
high risk for recurrence, this would provide excellent
opportunities for speciﬁc, indicated, (secondary)
prevention.
For recurrence prevention, antidepressants are most
often used,12 24 but unwillingness to take antidepres-
sants, non-adherence and discontinuation due to
adverse effects limit their applicability.25–27 As an alterna-
tive, preventive cognitive psychotherapies have been
developed (eg, mindfulness based cognitive therapy, pre-
ventive cognitive therapy and well-being cognitive
therapy),28–36 which seem to produce long-lasting bene-
ﬁcial effects.22 37 Nevertheless, recurrence-rates stay sub-
stantial, urgently calling for further improvements of
recurrence preventing therapy.
In that respect, if we better understand the mechan-
isms underlying vulnerability for recurrence in MDD, we
could (1) use their indicators as (bio)markers to
monitor/predict recurrence risk, and/or (2) use these
mechanisms to identify/develop novel targets for
improved and personalised preventive therapy in a preci-
sion medicine setting. This early identiﬁcation and strati-
ﬁed treatment of recurrence risk38 could potentially
reduce recurrent MDD’s disease burden.
However, understanding of mechanisms underlying
MDD-recurrence is limited to date. Although remitted
MDD-patients have already been studied for a number
of years,21 most studies investigate MDD during the
acute phase. However, to be able to differentiate
between trait factors (that remain present during remis-
sion and possibly constitute vulnerability for recurrence)
versus state factors (which are only present during an
MDD-episode), it is necessary to study patients during
remission. In addition, the actual predictive associations
of these possible trait factors with recurrence have to be
tested in long-term prospective follow-ups.
Thus far, the limited research that applied such a pro-
spective approach in remitted MDD-participants investi-
gated several factors as predictive of recurrence. While
associated with MDD onset, demographics (eg, gender)
generally do not predict recurrence; clinical and social
factors seem to be more predictive. Regarding clinical
factors, the number of previous episodes is among the
strongest predictors,39 together with residual depressive
symptoms.19 In addition, MDD family history, comorbid
axis I disorders, age of onset and last episode duration
and severity have been suggested as predictors.15 19 40–46
Furthermore, personality characteristics (coping style
and personality traits) and social factors (experiencing
daily hassles) have been found to be predictive
although ﬁndings remain largely inconsistent. In add-
ition, in our previous study a 71% variance in time to
5.5 years recurrence remained unexplained,47 48 and
only few actual predictive factors were potentially
modiﬁable.
As indicated, the pathophysiology behind these
factors’ predictive properties for recurrence remains far
from understood. For example, residual symptoms
predict recurrence in a short-term interval but seem less
predictive in the long-term interval.49 This indicates that
residual symptoms may not constitute a vulnerability
trait, but rather reﬂect the early initiation of a new
episode or an earlier episode not yet in full remission.
In addition, the predictive effect of previous episodes
can be explained due to scarring (increasing vulnerabil-
ity directly resulting from experiencing previous epi-
sodes) or high premorbid vulnerability (pre-existing
abnormalities leading to previous episodes and new
recurrences).50–52 From the prediction perspective,
these pathogenetic differences might seem a merely aca-
demic question. However, identifying the mechanisms
underlying MDD-recurrence is essential to discover
better potential targets for innovative preventive inter-
ventions to increase resilience.
Study aims and outline
Based on the above, the present study aims at advancing
the knowledge on (1) factors that are associated with
iThe terms relapse and recurrence are used in the literature and
deﬁned as new MDD-episodes within or after 6mths recovery,
respectively. However, empirically there is no clear evidence for this
distinction. We hereafter will name both recurrence for clarity.
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recurrent MDD-vulnerability, (2) how these factors are
related with each other, (3) their predictive association
with prospective recurrence and (4) their change
during recurrence.
In order to do so, we will initially compare fully remit-
ted unmedicated recurrent MDD-participants to
matched healthy controls. Subsequently, we will monitor
recurrence(s) in the MDD-participants during a 2.5-year
follow-up and repeat measurements when an
MDD-participant experiences a recurrence during
follow-up. Below, we will ﬁrst outline our theoretical
framework to provide background for our hypotheses
regarding the speciﬁcally selected factors that we will
investigate.
Theoretical framework
Based on preliminary ﬁndings, theoretical literature,
and observations from adjacent ﬁelds, several theories
have been developed to explain recurrence pathogen-
esis. Here, using a stratiﬁed approach, we aim to intro-
duce and integrate theories from four distinct selected
levels of perspective:53 54 symptomatology, affective
neuropsychology, brain circuits and endocrinology/
metabolism (ﬁgure 1).
Symptom level
A disturbed balance between negative and positive
valence systems seems to lie at the heart of MDD symp-
tomatology.54 Regarding negative valence systems,
MDD-patients suffer from for example, negative affect,
rumination and dysfunctional cognitions. While negative
cognition and processing styles as rumination usually
resolve after remission, they may remain present in
latent form, and can be reactivated during (mild) dys-
phoria, which is conceptualised as ‘cognitive reactiv-
ity’.50 55 56 Interestingly, latent dysfunctional attitudes,
increased cognitive reactivity and rumination have all
been found to predict recurrence in remitted
MDD-participants.57 58 Relating to negative but also posi-
tive valence systems, anhedonia (inability to experience
pleasure) is one of MDD’s core symptoms. Apart from
the ability to experience joy, the rewarding effect of
pleasure can also have a motivational function: pleasur-
able events appear to reinforce behaviour leading to
these events (conditioning). This implies that experien-
cing pleasure is a necessary stimulation to learn associa-
tions between stimuli and (pleasurable) outcomes and
move an individual to perform certain behaviours.
MDD-patients have difﬁculties in experiencing the
rewarding effects of positive/pleasurable events when
depressed, particularly relative to aversive stimuli, and
indeed have difﬁculties learning new beneﬁcial beha-
viours. This can also be observed in the form of psycho-
motor retardation and decreased positive affect.
However, anhedonia remains relatively underinvestigated
during remission, and it remains largely unknown to
what extent anhedonia can predict recurrence (see for
reviews59–63).
Affective neuropsychological level
This disturbed balance between negative and positive
valence systems at the symptom level may relate to nega-
tive biases in emotional processing at the affective
(‘hot’) neuropsychological level. Negative biases mani-
fest themselves when (dis)engaging (ie, attentional
bias), memorising, error-monitoring, shifting attention
between or regulating emotional information.64–74
Negative biases are thought to result from increased
negative attention on the self, and are thus related with
negative self-referential processing styles as rumination
and cognitive reactivity, which show a reciprocally
reinforcing relationship with negative affect.75 76
Increasing evidence shows that negative self-referential
processing and associated brain alterations contribute
greatly to the course and development of MDD.75 With
respect to reward processing, negative biases manifest in
decreased reward sensitivity (negative valence) and
increased aversive stimulus sensitivity (positive
valence).54 However, the precise relations between these
concepts, and to what extent these negative emotional
processing biases with associated brain alterations
remain present during remission, and can predict recur-
rence, remains largely unknown.77 78–80
Brain circuit level
From a neurobiological brain circuit perspective, dis-
turbed emotional processing at the affective neuro-
psychological level may be observed as an imbalance
between emotional (limbic/ventral) and regulating
(cognitive/dorsal) regions.81–86 Speciﬁcally, emotional
brain regions seem hyperactive in response to negative
stimuli but hypoactive to positive.87 In addition, regulat-
ing regions are generally hypoactive but may show com-
pensatory hyperactivity under certain circumstances, for
example, more automatic emotion regulation.88 This
may be explained by altered functional and structural
connectivity between these regions.89 Furthermore, dis-
turbed functioning of the default-mode network, a
network that is involved in self-referential processing
and is negatively correlated to regions that process atten-
tion and cognitive control, has consistently been
observed in MDD.90–94 Aberrations in the default-mode
network (ie, failure to deactivate default mode network
(DMN) regions)95 during tasks as well as DMN hyper-
connectivity96 during rest have been observed in MDD.
DMN aberrations have been associated with emotional-
cognitive disturbances and increased negative self-focus,
such as rumination.58 75 94 97–106
Especially anhedonic MDD-patients have a decreased
ability to change behaviour in relation to rewards, which
appears to persist after remission.59 107 This reduced
reward responsiveness might be related to blunted
phasic dopaminergic signalling. Indeed, reinforcement
learning appeared impaired in depressed MDD-patients
versus controls, with blunted reward signals in the
ventral striatum, and increased compensatory ventral
tegmental area activations when thirsty patients were
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learning associations between stimuli and water deliv-
ery.108 Furthermore, MDD-patients show reduced reward
anticipation and are less prone to exert effort for a
potential reward.59 These abnormalities also appear
present in participants prone to develop MDD.109 Also,
recognition of reward-related stimuli appeared most dif-
ﬁcult and associated with most impaired brain activities
in the N. accumbens, anterior cingulate cortex (ACC)
and ventromedial prefrontal cortex in patients with
chronic recurrent MDD.110 Thus, dopaminergic
reward-related brain circuits seem to be of importance
in recurrence of MDD. However it remains unclear
whether such abnormalities in reward-related learning
are also associated with recurrence.
Despite increasing research efforts to delineate these
brain circuits, it is hardly investigated how the default-
mode network and its relations to other cognitive net-
works and emotion-processing and reward circuits func-
tion in remitted recurrent MDD-participants.111–116 In
addition, it has been examined scarcely how alterations
in these circuits can predict recurrence in remitted
MDD-participants.117 118
Endocrinology and metabolism
These disturbed brain circuits may be associated with
alterations in endocrinology and metabolism. From an
endocrinological viewpoint, the principal stress system—
the hypothalamic-pituitary-adrenal (HPA)-axis—has
Figure 1 Theoretical framework. Schematic representation of the theoretical framework of the present DELTA-neuroimaging
study. The four selected levels of perspective (endocrinology/metabolism, brain circuits, affective neuropsycholoy and symptoms),
their respective subdomains, and their connections have been depicted. The horizontal straight arrows show potential bidirectional
relationships (for readability bidirectional relationships between eg, anhedonia and cognitive reactivity are not shown), the
horizontal curved arrow shows membrane fluidity balance, coloured arrows show potential connections, dashed arrows show
inhibiting effects and vertical grey arrows show possible underlying pathways. Abbreviations used: DELTA, Depression
Evaluation Longitudinal Therapy Assessment; DHEAS, dehydroepiandrosterone-sulfate; GABA, γ-aminobutyric acid; HPA,
hypothalamic-pituitary-adrenal; PFC, prefrontal cortex; vStr, ventral striatum; VTA, ventral tegmental area; TPN, task positive
network; DMN, default mode network; dACC, dorsal anterior cingulate cortex; pgACC, pregenual anterior cingulate cortex; Amy,
amygdala; ‘Hot’ neuro-Ψ, affective neuropsychology; Cogn. react., cognitive reactivity; Dysf. attit., dysfunctional attitudes.
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been studied extensively in MDD.119 In combination
with, for example, ﬁndings in ﬁrst degree relatives, our
own research indicates that HPA-axis hyperactivity is an
endophenotypic trait, with higher diurnal cortisol and
altered dehydroepiandrosterone-sulfate (DHEAS) that
remain during remission,21 120 121 and potentially
predict recurrence.122–125 Interestingly, HPA-axis activity
can be linked with brain circuit alterations. For example,
the effects of stress on limbic network structure in MDD
could reﬂect chronic HPA-axis hyperactivation-induced
allostatic load (eg, reducing hippocampal volumes), pre-
disposing to MDD(-recurrences).126 127 Vice versa, the
HPA-axis is controlled by the limbic system,128 through
medial prefrontal connections with amygdala and
hypothalamus.129
Moreover, interestingly, we previously showed a bidirec-
tional relationship between fatty acid metabolism and
HPA-axis activity.130 131 Fatty acids are main constituents
of (nerve) cell membranes and myelin, and so inﬂuence
important (neuro)physiological mechanisms such as
exocytosis, membrane-anchored protein function, mem-
brane ﬂuidity, second messenger system activity and
white matter integrity.132 133 Furthermore, they are pre-
cursors of eicosanoids and are associated with brain-
derived neurotrophic factor, which regulate inﬂamma-
tory homeostasis and nervous system architecture,
respectively.9 133–136 We previously showed that besides
alterations in ω-3 fatty acids, MDD is additionally asso-
ciated with more general alterations in overall fatty acid
metabolism, also in recurrent MDD.137–140 However,
inconsistencies remain, and recurrent MDD has only
been sparsely investigated. Moreover, given the wide-
spread involvement of fatty acid metabolism in brain
physiology, associations between fatty acid metabolism
and brain circuit alterations can be expected,9 136 141
but remained largely uninvestigated thus far.
Furthermore, glutamate/glutamine and γ-aminobutyric
acid (GABA) neurometabolism is currently considered an
interesting additional system in MDD and its recurrence
too. Glutamate and GABA are the major excitatory and
inhibitory neurotransmitter, respectively, and have been
implicated in MDD-pathophysiology.142 143 For instance in
depressed MDD-patients, excess excitotoxic synaptic glu-
tamate have been suggested to cause less pregenual ACC
deactivation when viewing negative emotional pic-
tures.144 145 Nevertheless, previous investigations of glutam-
ate/GABA in depressed MDD-patients remain
contradictory,146 147 and while abnormalities might nor-
malise after remission,148 this is only sparsely investi-
gated,147 149 especially not in recurrent MDD.
Summary of theoretical framework
MDD can be characterised by multiple alterations across
systems that remained distinct thus far, but potentially
can be integrated. At the symptom level, MDD-patients
show a disturbed balance between negative and positive
valence systems with increased latent negative affect,
rumination, dysfunctional cognitions and cognitive
reactivity, together with anhedonia. This may be asso-
ciated with negative emotional biases at the affective
neuropsychological level. These negative emotional
biases may relate to an imbalance between emotional
and regulatory brain circuits, DMN hyperconnectivity/
activity and might also be associated with a disturbed
brain reward circuit. These brain circuit alterations seem
closely connected with HPA-axis alterations, which seem
bidirectionally related with fatty acid and glutamate/
GABA-metabolism (ﬁgure 1). However, even if previous
research studied remitted MDD-participants, these altera-
tions were mostly investigated in isolation and only cross-
sectionally. Consequently, it remains largely unknown to
what extent these alterations (1) persist during remission,
(2) are associated with each other, (3) are predictive for
recurrence and (4) change during recurrence.
Hypotheses
With the aim of the current ‘DELTA-neuroimaging’ study
to integrate these factors and test their association with
recurrence in a prospective cohort-study of stably remitted
unmedicated recurrent MDD-participants, we ﬁrst will
compare MDD-participants with carefully matched con-
trols at baseline, and subsequently we will follow-up the
MDD-participants for 2.5 years while monitoring recur-
rences. Moreover, we will invite recurring participants to
repeat baseline measurements, together with matched
remitted participants. Following this line of research we
will investigate the following speciﬁc hypotheses:
1. Compared to matched never-depressed controls,
remitted unmedicated recurrent MDD-participants
will show (ie, a trait effect):
A. At the symptom level, a disturbed balance
between negative and positive valence systems
with increased rumination, dysfunctional cogni-
tions, cognitive reactivity and anhedonia.
B. At the affective neuropsychological level,
increased negative biases in emotional processing
when (dis)engaging (attentional bias), memoris-
ing, shifting attention between, and regulating
emotionally valenced stimuli.
C. At the brain circuit level, altered grey/white
matter structure and function/connectivity of
emotional/regulating regions, reward brain cir-
cuits and the default-mode network, also relative
to other networks of the brain, with speciﬁcally:
i. More ventral and less dorsal region activation
when viewing emotional pictures.
ii. Less connectivity between ventral and dorsal
regions.
iii. More activation of dorsal regions during a
reappraisal emotion regulation task.
iv. Blunted ventral striatum and increased
ventral tegmental area reward-signals.
v. Hyperconnectivity within and dominance of
the default-mode network at rest, which
becomes more pronounced after sad
mood-induction.
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D. At the endocrinology and metabolism level,
altered HPA-axis activity, fatty acid metabolism
and emotional network GABA/glutamate, with:
i. Higher morning and evening HPA-axis corti-
sol and relatively lower DHEAS, which
becomes more pronounced after sad
mood-induction.
ii. Lower degree of fatty acid unsaturation,
chain length, peroxidisability and ω-3/
ω-6-ratio.
iii. More glutamate and less glutamine/GABA
signals in the basal ganglia and pgACC,
which becomes more pronounced during sad
mood-induction.
2. In remitted unmedicated recurrent MDD-
participants the above systems will be related with
clinical characteristics (number of previous episodes,
residual symptoms and age of onset) and each other,
and these latter mutual relationships will differ from
those in matched never-depressed controls.
3. In remitted unmedicated recurrent MDD-
participants, above alterations will predict prospective
2.5-year follow-up symptom course, speciﬁcally:
A. Time until recurrence
B. Cumulative number and severity of MDD-episodes
C. Course of depressive (residual) symptoms.
4. The above alterations will become more pronounced
during repeated measures in recurrent MDD-
participants experiencing a recurrence during
follow-up, in comparison to repeated measures in
matched remitted recurrent MDD-participants (ie, a
state effect).
METHODS
Design
The present study consists of two stages (ﬁgure 2). First,
using a cross-sectional patient-control design, we will
compare remitted recurrent MDD-patients with matched
never-depressed controls, to identify traits that remain
present during remission and that are associated with
recurrent MDD-vulnerability. Second, using a prospect-
ive cohort-design, we will follow-up the patients. During
follow-up, we will measure depression symptoms every
4 months, to see whether we can predict clinical course
from baseline measures. Moreover, when we detect a
follow-up recurrence, we will invite the respective patient
to repeat several baseline measures. In addition, we will
invite remitted patients (matched on duration of
follow-up, gender, age, educational level and working
class) to repeat the measures as well. While this repeated
measures design is not required to predict recurrence, it
is of interest as it allows us to identify depression state
versus trait-effects.
In sum, we will ﬁrst test for trait factors associated with
MDD-vulnerability by contrasting vulnerable (remitted
recurrent MDD) versus resilient (never-depressed con-
trols) participants. Subsequently, also in order to further
delineate whether these identiﬁed factors are causal, con-
sequences or confounders, we will test their predictive
effect of prospective recurrence during follow-up in the
remitted recurrent MDD group. Finally, we aim at disen-
tangling state and trait effects by repeating measures in
patients during recurrence versus matched patients who
are in current remission. Below, we will describe the
population, measures, procedure and analyses in detail
Figure 2 Study design. Figure 2 depicts the study design of the present Depression Evaluation Longitudinal Therapy
Assessment (DELTA)-neuroimaging study. Different part of the study are shown in chronological order from left to right. For a
description of the contents of questionnaire booklets and tasks we refer to the online supplementary text. After screening,
recruited patients and controls participate in the initial assessment where we check inclusion and exclusion criteria, register
variables and covariates of interest, prepare the mood induction and mail questionnaire booklet I and Salivettes. During the
subsequent first study session we will take fasting blood samples, perform the affective neuropsychological tests, perform the sad
mood-induction, explain the experience sampling method (ESM) and the emotion regulation functional MRI (fMRI) task, and
hand out the ESM-psymate and questionnaire booklet II. Subsequently, participants come to the MRI-session, where we take
structural (T1-weighted and diffuse tensor imaging (DTI)) and fMRI-scans (neural and sad mood induction resting state,
reinforcement learning, cued emotional conflict, emotion regulation), as well as γ-aminobutyric acid (GABA)-edited MR
spectroscopy (MRS) of the basal ganglia and pregenual anterior cingulate cortex. Next, we monitor the patients by calling them
every ∼4 months to assess recurrence. In case we detect a recurrence, we invite the respective patient—together with matched
non-recurrent patients—to repeat part of the baseline assessments (blood samples, affective neuropsychological tests, structural
MRI, fMRI (resting state, reinforcement learning) and MRS).
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in that order, additional information can be found in the
online supplementary tables S1 and S2.
Population
Inclusion criteria
To maximise contrast for recurrent MDD-vulnerability,
without confounding effects of medication or current
MDD-symptoms, we will include recurrent MDD-partici-
pants (≥2 previous MDD-episodes as assessed using the
structured clinical interview for Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV)
diagnoses (SCID)150 who are in stable remission (≥8 weeks
with a 17-item Hamilton Depression Rating Scale
(HDRS)≤7 and not fulﬁlling the criteria for a current
MDD episode (as assessed using the SCID during inclu-
sion)).151 Speciﬁcally, we will include participants aged 35–
65 years, to include a homogeneous age group, and to pre-
clude conversion to bipolar disorder due to later experi-
ence of (hypo)manic episodes. Of note, despite overall
high recurrent MDD vulnerability and homogeneity
regarding, for example, age, we expect this group of
MDD-patients to exhibit considerable variance in prospect-
ive recurrence rates. For example, in our previous
research22 30 47 152 the range in previous MDD-episodes
was from 2 to 60, and we will now include patients with
none or only a single episode in the past 10 years. We
expect that this will lead to a relapse rate of ±50% during
the 2.5 years follow-up, providing excellent within-group
contrasts for prospective recurrence in this overall highly
vulnerable group. Second, we will include relatively resili-
ent controls without personal (SCID) or ﬁrst degree famil-
ial psychiatric history, carefully matched for age, sex,
educational level, working class and ethnicity.
Exclusion criteria
While comorbidity in general will not be an exclusion
criterion because it may be an important predictor, in
order to obtain a homogeneous sample we will exclude
participants with current diagnoses of alcohol/drug
dependence, psychotic or bipolar, predominant anxiety
or severe personality disorder (all SCID); standard MRI
exclusion criteria (eg, metal objects in the body, claus-
trophobia); electroconvulsive therapy within 2 months
before scanning; history of severe head trauma or neuro-
logical disease; severe general physical illness; no
Dutch/English proﬁciency. To minimise inclusion bias,
we will try to familiarise mildly claustrophobic partici-
pants in a mock MRI-scanner to enable actual
MRI-assessments. If this does not succeed, we will only
perform non-MRI assessments. All participants have to
be without psychoactive drugs/medication for >4 weeks
before assessments. We will allow incidental benzodi-
azepine use, but this must be stopped after informed
consent and ≥2 days before assessments. Despite pos-
sible effects of psychotherapy we will not exclude
current or past psychotherapy due to feasibility reasons.
However, we will assess all forms of therapy used, report
these and treat them as covariates in our analyses.
Recruitment
To minimise selection biases, we will recruit both groups
through identical advertisements in freely available
online and house-to-house papers, posters in public
spaces and from previous studies in our and afﬁliated
research centres. One previous study from which we will
recruit participants is the Depression Evaluation
Longitudinal Therapy Assessment (DELTA)-study.30 We
recently completed the 10-year follow-up of this rando-
mised controlled trial assessing the protective effects of
8 weeks preventive cognitive therapy on recurrence in
recurrent MDD.22 In this long-term study, we not only
obtained detailed psychological, but also obtained bio-
logical measures, which can be linked to data obtained
in the present study in the same participants. Of note,
the original DELTA sample was recruited like the pro-
cedure for new participants for the present recruitment,
among others through newspaper advertisements. By
DELTA-study design, 50% of the original DELTA sample
received randomised preventive cognitive therapy
10 years ago, however, as (1) previous psychotherapy was
not an exclusion criterion in the present total sample
and (2) the preventive cognitive therapy intervention
was more widely implemented in the Netherlands since
the DELTA-study, non-DELTA participants could also
have undergone this treatment. This allows the add-
itional interesting option to collect data on previous
treatments in all participants in order to estimate the
magnitude of this possible treatment effect. Finally, we
will recruit additional recurrent MDD-participants from
patients previously treated by the AMC or afﬁliated
general practitioners and psychologists.
Measures
See online supplementary tables S1 and S2 for full
details.
Structured interview and questionnaires
The SCID is widely accepted as structured diagnostic
interview to adequately assess DSM-IV deﬁned psychi-
atric disorders.150 153 Questionnaire-booklets I–IV (see
online supplementary text) include questionnaires on
depressive symptoms (eg, HDRS), stress and life events
(trauma and daily hassles), personality (neuroticism and
coping) and lifestyle (physical activity, sleep and diet).
Mood induction
We will prepare a negative and neutral mood-induction
procedure by asking participants to recall and describe a
personal sad and neutral memory,56 from which we will
make sad and neutral personalised scripts. In addition,
we will request participants to listen to and rate ﬁve dif-
ferent fragments of sad/neutral music on a dedicated
website (accessible on request). This type of provocation
(combining sad music with autobiographical recall) has
been shown to effectively induce transient dysphoric
mood states.56 We used this mood induction to test (1)
mood-induced changes in dysfunctional attitudes
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(cognitive reactivity), (2) HPA-axis activity and (3) brain
networks.
Affective neuropsychological tests
The affective neuropsychological tests all assess emo-
tional processing. The exogenous cueing task allows
disentangling of attentional engagement and disengage-
ment components in attentional bias.66 154 The facial
expression recognition task measures interpretation of
key emotionally valenced social signals of varying inten-
sity (morphed faces).69 71 155 The emotional categorisa-
tion task assesses response speed to self-referent positive
and negative personality descriptors, the emotional
memory task follows up on this task by assessing surprise
(free) recollection memory of these personality descrip-
tors.69 71 155 The internal shift task examines capacity to
shift attention between working memory contents in
response to emotional and non-emotional material.156 157
For matching purposes, we will estimate premorbid intel-
ligence with the Dutch adult reading test.158
Experience sampling method
Momentary assessment techniques are ideal for pro-
spective examination of dynamics of observed behaviour,
and enable to capture the ﬁlm rather than a snapshot of
daily life.159–162 Experience sampling method (ESM) is a
structured diary method developed to study participants
in their daily surroundings, applicable via a validated
interactive ESM-palmtop. We will obtain ESM-ratings
regarding positive and negative affect—hypothesised to
be separate but correlated latent factors163—and pos-
sible inﬂuencing factors (e.g. (social) activities), for
6 days with 10 semirandom measurements/day prefer-
ably between the ﬁrst study-session and MRI-session.
MRI-scans (two blocks)
In the ﬁrst block, after locater and reference scans, a
structural T1-scan will provide high resolution three-
dimensional anatomical information. Then we will
obtain a resting-state scan after neutral mood-
induction,98 followed by a reinforcement learning
fMRI-task which applies a Pavlovian-learning paradigm
delivering the thirsty participants small amounts of sweet
or bitter solution at 80–20% probabilities after condi-
tional stimuli. This enables assessment of reinforcement
learning circuitry.108 Subsequently, using a GABA-
speciﬁc MEGA-PRESS sequence we will obtain an edited
1H J-difference MR spectroscopy (MRS)-scan of the
basal ganglia to measure glutamate and GABA.144 164–166
A diffusion-weighted imaging (DTI) spin echo sequence
will assess white matter structure.167 After a break, in the
second block, participants will perform the cued
emotional conﬂict fMRI-task, which will test cue related
conﬂict anticipation and response related cognitive
control.168 Then, the emotion regulation task will
measure brain activity in emotional and regulatory brain
networks during attending and regulating (distancing
technique) positive, negative and neutral emotional
stimuli. Subsequently, we will make another resting-state
scan, but this time after a negative mood-induction. In
combination with the neutral resting-state scan from the
ﬁrst block, this sad mood-induced resting-state scan will
allow assessment of mood-induced changes in brain
network interactions.98 Finally, we will make another
MRS-scan of the pgACC. In the follow-up MRI-scan-
session we will repeat the structural, resting state
(without mood-induction), reinforcement learning and
MRS-scans. During scanning we will record heartbeat
and breathing in order to correct for their
movement-effects.
Blood measures
From collected blood tubes, we will use 1×4.5 mL EDTA
blood for fatty acid analyses in washed erythrocytes (as a
model of neuronal membranes),139 which we will store
for future lipidomic analyses. We will use 7 mL EDTA
and PaxGene blood collection tubes for future genomic
analyses (eg, serotonin, dopamine, glutamate/GABA-
cascades, one-carbon metabolism or HPA-axis recep-
tors).38 169 170 We will store platelet-poor plasma from
5 mL citrate blood and also store plasma from 4.5 mL
EDTA and lithium-heparine blood collection tubes for
future use (eg, metabolomics and inﬂammation).171
Salivary measures
As described below and in the online supplementary
text, we will instruct participants to collect salivary
samples over the day using Salivettes (Sarstedt,
Nümbrecht, Germany). Saliva reﬂects blood cortisol and
DHEAS-concentrations, but enables minimally intrusive
and relatively stress free assessment.120 172 173
Procedure
We will regularly train all assessors and experienced psy-
chiatrists will closely supervise the assessment proce-
dures. We will discuss difﬁcult assessments; in case of
disagreement we will make a conservative decision (eg,
exclusion).
Preparation
Initial assessment and mood-induction
We will telephonically screen recruited participants for
potential eligibility. In a ﬁrst interview (telephonically or
face-to-face), we will check inclusion and exclusion cri-
teria. After obtaining informed consent we will register
psychiatric and somatic treatment history, covariates of
interest and potential confounders. Furthermore, we will
mail questionnaire-booklet I (see online supplementary
text) and Salivettes, with detailed instructions. In add-
ition, we will prepare the mood-induction procedure.
Baseline visits
First study-session
We will instruct participants to arrive after ≥8 h fasting.
First, we will collect blood samples by venipuncture,
which we will directly bring to the laboratories.
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Subsequently, we will allow participants to eat and drink,
with the exception of caffeinated drinks.
Next, we will instruct participants to perform the
neuropsychological tests in two blocks with a break in
between, and measure waist circumference140 (see
online supplementary text). After neuropsychological
testing, we will explain the scanning procedure and train
the participant for the emotion regulation fMRI-task,
which will be performed in the scanner (see online sup-
plementary table S2). After a 15-min break, participants
will undergo the sad mood-induction. Before and dir-
ectly after sad mood-induction, we will request partici-
pants to ﬁll out a Dysfunctional Attitudes Scale (two
randomised counterbalanced versions),56 174 175 rate
their sadness on a visual analogue scale and collect
saliva (using Salivettes).
Finally, we will explain and instruct participants about
the ESM (see above). In addition, we will provide partici-
pants with questionnaire-booklet II (see online supple-
mentary text) to ﬁll out before the MRI-session.
MRI-session
We will instruct participants to arrive thirsty, that is, ≥6 h
without drinking and ≥2 h without eating juicy food (for
the reward learning task). On a Philips Achieva XT 3 T
MRI (Philips Medical Systems, Best, the Netherlands),
using a 32-channel receiver headcoil, at the University of
Amsterdam, Spinoza Center, we will scan two consecutive
blocks of approximately 60 min each (see above), sepa-
rated by a break. During the scanning procedure, we will
again perform the mood-induction (neutral/sad) in a
slightly modiﬁed version as described previously.56 We
will ask participants to listen to their selected most
neutral/sad music piece and meanwhile read their per-
sonal sad/neutral memories presented on a screen in the
scanner (during 5 min), directly before the resting state
scans. Finally, we will debrief participants, complete
questionnaire-booklet III (see online supplementary
text), and obtain post-scan ratings of stimuli presented
during the tasks.
Follow-up
Monitoring
We will follow-up the recurrent MDD-participants by
regular (every ∼4 months) phone-calls (SCID and
HDRS) and questionnaire-booklet IV (see online supple-
mentary text). To maximise recurrence detection rates,
we will also instruct participants to contact us at the
moment they subjectively experience a recurrence and
inform a person close to them of these instructions.
To allow for the possibility to disentangle state and
trait effects, when we detect a recurrence (SCID), we
will invite the respective recurring participant and a
matched remitted (MDD-participant to repeat several
baseline measurements (see below). We will preferably
scan participants before they (again) start antidepres-
sants, but—in order to maintain power—this will not
be an exclusion criterion for the follow-up scan/
measurements. Thus, when patients experience a
relapse and agree to participate in the study again, they
will be matched with recurrent MDD-participants that
are in remission (SCID and HDRS≤7) and meet match-
ing criteria. We will conduct matching based on group-
level characteristics of relapse patients versus control
patients (mean and distribution of follow-up time, age,
years, sex, educational level and working class). In this
way, we also aim to include relatively more control
patients (relapsed:control patients ratio of 1:1.5), with
the goal of increasing power. These matched partici-
pants have to be currently euthymic but can have had a
prior relapse, thus after the baseline measurement, or a
relapse during follow-up after second participation. The
reason for this approach is that we are interested in
comparing the effect of depression (state) versus
depressive vulnerability (trait), instead of simply com-
paring more vulnerable patients to stable patients. This
will give us insight into the pathophysiology of relapse
versus remission; it allows to examine which factors stay
the same, and which factors show change when patients
relapse. Potential in-between recurrences will, however,
be examined as a potential confounder in the ﬁnal
analyses. Nevertheless, a participant will not be
included more than once in the follow-up repeated
measurements (scanning/neuropsychology), in order to
exclude the possibility of learning effects and habitu-
ation in testing/scanning and prevent complex covari-
ance structures.
Repeated measures in recurring and matched
MDD-participants
We will repeat questionnaire-booklets I–III (see online
supplementary text), blood sampling and neuropsycho-
logical testing. In addition, we will repeat part of the
MRI-scan in an ∼1 h scan-session (see online supple-
mentary table S2). To minimise learning effects, we
will use randomised counterbalanced versions of tasks
when applicable. We will not repeat the mood-
induction.
Statistical analysis plan
E-infrastructure and software
We will store raw and cleaned data on dedicated servers
and make use of available e-infrastructure bioinformatics
networks where necessary.176 We will use a variety of pro-
grammes under which SPSS (IBM SPSS, Chicago,
Illinois, USA).
Data preparation
Distributions and missing data
We will inspect distributions and remove (multivariate)
outliers and data noncompliant to the protocol (eg,
saliva samples outside time-range or chance level (neuro)
psychological responses). We will transform non-normally
distributed data where possible, otherwise we will apply
non-parametric tests or bootstrapping if applicable. For
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extensive missing data at random, we will use multiple
imputation where necessary and possible.139 177 178
(Neuro)psychological tests
For the (neuro)psychological tests, we will calculate
summation-scores where applicable.71 155
ESM
We will prepare ESM-data using developed algorithms.
In brief, we will include data in the analyses for which
>30% ESM reports are within 25 min after the pro-
grammed time of the beep,179 to ensure reliability.180
From the ESM-data we will test the factor structure of
the positive and negative affect measures using factor
analysis, also at the within-participant level (see online
supplementary table S1).163
MRI-data
We will perform standard preprocessing using dedicated
software.181 182 After realignment, we will co-register func-
tional scans to the structural scan, and thereafter normal-
ise to the standard Monteal Neurological Institute (MNI)
brain or a DARTEL template (Diffeomorphic Anatomical
Registration Through Exponentiated Lie Algebra) for
more ﬂexible group normalisation, and smooth. For the
different fMRI paradigms, we will perform ﬁxed effect
analyses on single-participant level with linear regression
techniques (general linear models). For DTI-scans, we
will use tract-based spatial statics for general effects and
tractography for a priori deﬁned tracts of interest.183
Neurometabolism and HPA-axis
We will quantify glutamate and GABA based on acquired
MRS-spectra.165 From concentrations of all measured
fatty acids, we will calculate overall fatty acid unsatur-
ation, chain length and peroxidisability using dedicated
indices.139 Finally, we will calculate cortisol/DHEAS-ratio
as indication of HPA-axis balance.184
Statistical analyses
The statistical analysis protocol has been written, and
the study statistics will be carried out, under close super-
vision of a statistical specialist.
Power analyses
Power analyses for continuous and categorical outcomes
of the cross-sectional and prospective analyses show
adequate power to detect small to medium effect-sizes
with 60 patients and 40 controls (see online supplemen-
tary text). This is in line with previous comparable
research that found signiﬁcant effects in smaller
samples.66 Power calculations for studies involving MRI
remain hard and are not used routinely (for an
approach see eg, Mumford and Nichols,185 Hayasaka
et al186 and Murphy et al187). Currently, there is consen-
sus that groups of ≥20 usually yield sufﬁcient power in
MRI-studies to detect moderate differences in regions of
interest.
Based on these power estimations and feasibility
aspects, we will test our ﬁrst hypotheses on acquired
scans from 60 recurrent MDD-participant and 40 con-
trols, which is for baseline group comparisons a number
more than common in MRI studies, also in studies with
a comparable design.188 Regarding feasibility, next to
scanning costs which limit participant number, recruit-
ment efforts were estimated based on our previous
studies. These efforts will be manageable with this
sample size of speciﬁcally remitted recurrent MDD-
patients that have to be medication free.30
Regarding the prospective analyses, in a previous study
with recurrent MDD-participants, we observed ∼50%
recurrence rate in 2.5 years.30 We therefore expect
2×20–30 participants to be eligible for a second scan
and subsequent comparisons, allowing for some drop-
outs. Based on previous research in comparable samples
we expect low attrition rates.22 30 47 152 Moreover, all par-
ticipants can be included in the Cox-regression analyses,
since these can adequately deal with attrition (outcome
measure incorporates time to event or censored end of
observation). As not all participants will be identiﬁed
when the recurrence is present and/or not all recurrent
patients will be available for a second scan, we expect to
obtain two groups of ±20 patients with or without a
recurrence up who will be scanned again during follow.
We perform a large set of measurements, which
carries the risk of false positives. However, as we will
perform analyses according to analysis-plans which are a
priori speciﬁed, we will do so for independent a priori
hypotheses. In addition, we will use multivariate analysis
techniques (eg, machine-learning) to further reduce the
risk of chance ﬁndings. Nevertheless, although our
sample size will exceed the level of a pilot-study, espe-
cially for the prediction measures that we will identify we
will need new samples to replicate our ﬁndings.
Finally, next to our a priori power analyses, we will
perform post hoc power analyses of our outcomes once
the data have been analysed.
Descriptive data
We will provide descriptive statistics and compare groups
using χ2 tests and independent samples t tests where
applicable.
First and second hypotheses
For the ﬁrst hypotheses we will compare the remitted
recurrent MDD-group with the control-group using
(multiple) general linear models or linear mixed models
(eg, complex repeated measures/covariance structure,
nested data, missing data), where applicable.189 We will
present results uncorrected and corrected for confoun-
ders (factors differing between groups with p<0.1) and/
or covariates of interest, using propensity scores where
applicable.190 Independent variables will be group
(recurrent MDD vs control), potential covariates, their
interaction(s) and confounders; the selected outcome(s)
for a given speciﬁc hypothesis will be dependent variable
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(s). If interaction effects do not contribute to the model,
we will remove them to obtain the most parsimonious
models. For the second hypotheses we will use compar-
able models, except that we will omit the control-group
(and consequently the group-variable and interactions)
from the models, and focus on effects of clinical vari-
ables of interest in the remitted recurrent MDD-group.
Third and fourth hypotheses
For the prediction analyses, we will use cox-regression
models to investigate prospective association between
baseline measures and time until ﬁrst recurrence. Using
time until ﬁrst recurrence as primary outcome measure
will provide additional modelable variance in the data
since such contrasts not only incorporate 50% recur-
rence, but also fast versus slow recurrence that may be
highly relevant from a clinical perspective. Furthermore,
in ﬁrst instance we are planning to only use the time
invariant baseline predictors. However, in a later stage,
we will incorporate the variables that we measure over
time, for example, the HDRS or rumination question-
naires, to see how changes in these parameters over
time are associated with future recurrence (eg, medi-
ation) and/or time until recurrence.
Next, we will model signiﬁcant univariate associations
in multiple regression models, with correction for other
confounders and covariates of interest related to recur-
rence (eg, number of previous episodes, residual symp-
toms, ‘daily hassles’ and coping style). Moreover, we will
analyse secondary outcomes (cumulative number, length
and severity of MDD-episodes and course of depressive
(residual) symptoms) using (multivariate) general linear
models or linear mixed models, where applicable. For
the fourth hypotheses, we will investigate change during
recurrence using repeated measures general linear
models or linear mixed models where applicable.
Additional analyses
To exploit the multimodal and multidimensional charac-
ter of our data, we plan to apply advanced statistical
methods to identify relevant multivariate patterns,
including machine learning, factor and network ana-
lyses.191–193
ETHICS AND DISSEMINATION
Ethical considerations
Regulation statement
We will conduct this study according to Declaration of
Helsinki principles (Seoul, October 2008) and the
Medical Research Involving Human Subjects Act
(WMO). The study is approved by the accredited
Medical Ethical Committee (METC) of the Academic
Medical Centre (AMC), teaching hospital of the
University of Amsterdam. We will obtain written
informed consent beforehand from all participants,
after careful and extensive written and oral information.
If desired, we will give participants up to 2 weeks to
consider their decision. Investigators will receive good
clinical practice training, in agreement with the AMC
research code.
Handling of data and documents
We will encode data and keep this data and blood
samples for at least 15 years. Only researchers directly
involved in the study will have access to encoded data,
the key will be with the researcher only. We will label
blood samples with anonymised patient numbers.
Benefits and risk assessment
There is no immediate advantage of participation for
participants, there are no interventions scheduled in
this study. MRI is non-invasive, so hardly any risks are
associated with this study. Therefore, the METC deter-
mined that no liability insurance is required. We will
inform participants and the reviewing accredited METC
if anything occurs, on the basis of which it appears that
disadvantages of participation may be signiﬁcantly
greater than was foreseen.
Because we recruit unmedicated participants with
moderate to high recurrence risk, it may be questioned
whether follow-up of these participants is ethically justi-
ﬁed. However, we will not actively propose tapering or
discontinuation of antidepressant therapy. Instead we
will only include participants who decided to stop anti-
depressants beforehand. In case we detect suicidality
during follow-up, we have a protocol available including
a consulting psychiatrist for emergency situations and
referral the most appropriate emergency service. We
therefore consider this study ethically justiﬁable.
In addition, advantages of participation and follow-up
will be that MDD-recurrence will be detected early so
prompt psychiatric treatment can be offered. In natural-
istic care there might be substantial patient and institu-
tional delays before recurrence is detected and
treatment can be started.194
Compensation
Participants will receive €75,- for their participation,
besides compensation for travel expenses. For comple-
tion of a follow-up scan we will pay €50,-.
Teaching
This study will provide training of PhD-students, and will
involve educational internships of medicine, psychology
and neuroscience bachelor-students and master-students
of the Universities of Amsterdam, Nijmegen and
Groningen and VU-university.
Dissemination
Public disclosure and publication policy
We will submit study-results for publication in peer
reviewed journals and presentation at (inter)national
meetings, taking into account relevant reporting guide-
lines (eg, Committee on Publication Ethics (COPE),
STrengthening the Reporting of OBservational studies
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in Epidemiology (STROBE)).195–197 We will regularly
notify participants of publication. Curated technical
appendices, statistical code, and anonymised data will
become freely available from the corresponding authors
on request.198
DISCUSSION
Summary
In summary, the current multimodal DELTA-
neuroimaging study will investigate recurrent MDD vulner-
ability by comparing remitted unmedicated recurrent
MDD-participants with carefully matched controls without
personal/ﬁrst degree familial psychiatric history.
Biopsychosocial assessments integrate four distinct levels
of perspective: symptomatology, affective neuropsychology,
brain circuits and endocrinology/metabolism.
Subsequently, the cohort of recurrent MDD-participants
will be followed-up to test to what extent baseline measure-
ments predict, and/or change during prospective recur-
rence. This will help to disentangle the pathophysiology
behind MDD-recurrence, and thereby provide (1) (bio)
markers identifying high-risk patients needing additional
preventive treatment, and (2) novel targets to improve the
treatments preventing against recurrences. Given MDD’s
highly recurrent nature, this knowledge has the potential
to substantially reduce MDD’s disease burden.
Limitations and strengths
Limitations
Several limitations of the current study should be noted
beforehand. First, the extensive assessment procedure
needed to measure all variables of interest and confoun-
ders will potentially lead to inclusion of participants that
are intrinsically aware of the necessity to perform clinical
research and readily willing to cooperate. Nevertheless,
this selection bias is inherent to translational neuroscien-
tiﬁc research, and the relatively large number of partici-
pants that will be included will increase external validity.
Moreover, testing the integrated hypotheses of the
current study is only possible by combining the different
assessments.
Second, to overcome potential confounding effects of
antidepressants and other psychotropic medication, only
participants who currently do not use these drugs will be
included. This may lead to selection of particular
patient subgroups that (1) experienced little beneﬁt
from previous medication trials, (2) are hesitant to use
these medications because of adverse effects or for prin-
ciple reasons, (3) experience other barriers to care (eg,
ﬁnancial) or (4) have an intrinsically lower vulnerability
to have severe recurrences. In addition, it may slow
down inclusion. However, this is the only way to study
the hypotheses at hand while eliminating confounding
effects of medication use. Furthermore, the participants
included in the current study may be a clinically relevant
representation of patients that do not want to take anti-
depressant drugs, for whom knowledge of underlying
vulnerability and measures to determine this vulnerabil-
ity might be of help to develop novel alternative treat-
ments to prevent recurrence risk.
Third, for practical reasons family history will be
determined by heteroanamnesis. This may lead to recall
or other biases. However, both under and over-
representation can be expected, so we expect this will
not result in systematic biases.
Fourth, DSM-IV diagnostic criteria will be used for
current study’s diagnoses, while the DSM-5 has already
been introduced. Since the classiﬁcation of depressive
episodes (ie, recurrences) have not changed in DSM-5,
this and our speciﬁc inclusion and exclusion criteria will
not lead to difﬁculties in translating the results when
DSM-5 will be used.
Fifth, the current study’s assessments will not include
measures of HPA-axis feedback (e.g. dexamethasone sup-
pression(/corticotropin-releasing hormone-challenge)
test).199 This was not included to prevent overburdening
of participants. While consequently the current study will
not be able to directly assess HPA-axis feedback, the
study’s seven salivary HPA-axis measures without pharma-
cological challenge during the baseline assessments will
provide an adequate indication of HPA-axis activity under
natural circumstances, including stress by mood
induction.120 172
Sixth, the current study’s MRI-measures will be made
using 3 T ﬁeld strength, while higher ﬁeld strengths are
also available. Although obviously higher ﬁeld strengths
increase signal to noise ratio, they may also have several
disadvantages.200 Higher costs and speciﬁc absorption
rates, together with increased risk for artefacts due to
for example, inhomogeneous transmit ﬁelds, more
extensive contraindications and peripheral nerve stimu-
lation limit high ﬁeld strength applicability. These disad-
vantages apply to clinical studies like the present one,
but even more to the clinical setting.200 Therefore, 3 T
ﬁndings may be more readily clinically translated than
ﬁndings at higher ﬁeld strengths, and could therefore
be more relevant from the clinical perspective.200
Seventh, while the combined cross-sectional patient-
control and prospective follow-up design of the current
study has great advantages, it brings along a balance
between two contrasts. First, the recurrent MDD-
vulnerability contrast in the comparison between highly
vulnerable patients and matched resilient controls; and
second the within patient-group contrast in time until
recurrence of fast recurrence during follow-up versus no
or late recurrence. Strongly increasing the ﬁrst contrast
by including only extremely high recurrence risk
patients entails the risk of decreasing the second con-
trast because all patients will experience fast recurrence.
The other way around, by including too many patients
with a low recurrence risk, the ﬁrst contrast may be dis-
advantaged because the traits will not be outspoken
enough to be detected. Therefore, also based on our
previous research, we opted to increase to ﬁrst contrast
by including relatively resilient controls, together with
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patients that have proven vulnerability for recurrent
MDD (ie, ≤2 previous MDD episodes). However, we did
not express any additional vulnerability criteria, for
example, time since last episode or higher number of
previous episodes, in order to (1) include recurrent
MDD-patients that form a naturalistic sample that is rep-
resentative regarding vulnerability and (2) not to
decrease the second contrast in time until recurrence.
Of note, we will not include single episode
MDD-participants. While this would enable comparisons
against a relatively low recurrence risk group, instead of
controls, this was deemed to be logistically even more
difﬁcult to achieve. Regarding the second contrast in
time until recurrence, based on our previous research
and our inclusion procedure, we expect a large spread
in the number of previous episodes (eg, from 2 up to
60) and time since last episode (eg, from 8 weeks up to
>10 years), which both imply modelable variance/con-
trast in prospective recurrence risk.201 With an expected
‘optimal’ distribution of 50% recurrence-rate during
follow-up, we think that our group would be the most
interesting and feasible group to study when looking for
factors that can predict imminent recurrence, in order
to (1) select participants that may beneﬁt from prevent-
ive treatment, and (2) identify pathophysiological
mechanisms that can be targeted in these participants to
prevent recurrence risk.
Finally, the current study does not include (rando-
mised) interventions. Therefore, it will not be possible
to say whether observed effects are causal in nature.
Nevertheless, the current study’s prospective, repeated
measures design can optimally select targets for future
randomised clinical trials to test the causal nature of
observed effects.
Strengths
The current study also has several distinct strengths.
Owing to its strict and speciﬁc inclusion-criteria,
matching-procedure and recruitment-procedure, the
contrast for MDD-vulnerability will be maximal, without
distortion due to important confounders: MDD-residual
symptoms and medication. In addition, the unique inte-
gration of a wide range of measures in a prospective
repeated measures design will allow disentangling of
recurrent MDD state-factors and trait-factors.
Furthermore, the study will be performed by an
experienced international multicentre research group,
combining expertise from all measured perspectives.
Additionally, the Netherlands’ relative limited geo-
graphic size and high level of social organisation make it
well suited for long-term follow-up research.
Next, ESM-results could set the stage for innovative
cost-effective e-health interventions. Moreover, the focus
on lifestyle factors (physical activity/diet) and their bio-
logical effects could provide more insight into recurrent
MDD-patients’ increased risk to develop cardiovascular
disease,9 as already acknowledged in the introduction.
By combining these lifestyle (biological) assessments
with investigation of (the neurobiology of) motivation,
the present study could lead to development of interven-
tions that help to motivate recurrent MDD-patients to
improve their lifestyle. This not only has the potential to
prevent recurrence, but also the highly comorbid cardio-
vascular risk.202
Conclusion
By integrating the symptom level, affective neuropsych-
ology, brain circuits and endocrinology/metabolism,
using a prospective repeated measures design in remit-
ted MDD-participants, the present DELTA-neuroimaging
study will provide more insight in recurrent
MDD-vulnerability. Increased insight will lead to novel
targets for (I) improved preventive therapy, and/or (II)
(bio)markers to monitor and/or predict recurrence risk.
Consequently, ultimately, it holds potential to alleviate
MDD’s highly recurrent course and reduce its currently
overwhelming global disease burden.
Author affiliations
1Department of Psychiatry, Academic Medical Center, University of
Amsterdam, The Netherlands
2University of Groningen, Neuroimaging Center, University Medical Center
Groningen, The Netherlands
3Program for Mood and Anxiety Disorders, Department of Psychiatry,
University of Groningen, University Medical Center Groningen, The
Netherlands
4Laboratory Genetic Metabolic Disease, Academic Medical Center, University
of Amsterdam, The Netherlands
5University of Groningen, Interdisciplinary Center Psychopathology and
Emotion regulation (ICPE), University Medical Center Groningen, The
Netherlands
6Laboratory of General Clinical Chemistry, Academic Medical Center,
University of Amsterdam, The Netherlands
7Department of Experimental Clinical and Health Psychology, Ghent
University, Belgium
8Department of Clinical Psychology, University of Groningen, Groningen,
The Netherlands
9Department of Clinical and Health Psychology, Utrecht University, Utrecht,
The Netherlands
10Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford,
UK
11Department of Psychiatry, Radboud University Medical Center, Nijmegen,
The Netherlands
12Donders Institute for Brain, Cognition and Behavior, Radboud University
Nijmegen, Nijmegen, The Netherlands
Contributors RJTM and HGR designed the study. RJTM and HGR drafted the
protocol and the manuscript. All authors contributed to development and
implementation of the study protocol. MWJK provided statistical advice. RJTM
and CAF conduct all participant-related study-procedures. All authors
contributed to editing the manuscript and read and approved the final
manuscript.
Funding This study is supported by unrestricted personal grants from the
AMC to RJTM (AMC PhD Scholarship) and CAF (AMC MD-PhD Scholarship),
and a dedicated grant from the Dutch Brain Foundation (Hersenstichting
Nederland: 2009(2)-72). HGR is supported by a NWO/ZonMW VENI-Grant
#016.126.059.
Competing interests None declared.
Patient consent Obtained.
Ethics approval The local ethics committee of the Academic Medical Center
of the University of Amsterdam approved this study (AMC-METC-Nr.:11/050).
Mocking RJT, et al. BMJ Open 2016;6:e009510. doi:10.1136/bmjopen-2015-009510 13
Open Access
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We will submit study-results for publication in peer
reviewed journals and presentation at (inter)national meetings, taking into
account relevant reporting guidelines (eg, COPE, STROBE). We will regularly
notify participants of publication. Curated technical appendices, statistical
code, and anonymised data will become freely available from the
corresponding authors on request.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The
epidemiology of major depressive episodes: results from the
International Consortium of Psychiatric Epidemiology (ICPE)
Surveys. Int J Methods Psychiatr Res 2003;12:3–21.
2. Greden JF. The burden of recurrent depression: causes,
consequences, and future prospects. J Clin psychiatry 2001;62
(Suppl 22):5–9.
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010:
a systematic analysis for the Global Burden of Disease Study 2010.
Lancet 2012;380:2163–96.
4. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology
of DSM-IV major depressive episode. BMC Med 2011;9:90.
5. Mathers CD, Loncar D. Projections of global mortality and burden
of disease from 2002 to 2030. PLoS Med 2006;3:e442.
6. Cuijpers P, Smit F, Oostenbrink J, et al. Economic costs of minor
depression: a population-based study. Acta Psychiatr Scand
2007;115:229–36.
7. Sobocki P, Ekman M, Agren H, et al. The mission is remission:
health economic consequences of achieving full remission with
antidepressant treatment for depression. Int J Clin Pract
2006;60:791–8.
8. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe.
J Ment Health Policy Econ 2006;9:87–98.
9. Assies J, Mocking RJ, Lok A, et al. Effects of oxidative stress on
fatty acid- and one-carbon-metabolism in psychiatric and
cardiovascular disease comorbidity. Acta Psychiatr Scand
2014;130:163–80.
10. Kraepelin E, Barclay RM, Robertson GM. Manic-depressive
insanity and paranoia. Edinburgh: Livingstone, 1921.
11. Angst J, Baastrup P, Grof P, et al. The course of monopolar
depression and bipolar psychoses. Psychiatr Neurol Neurochir
1973;76:489–500.
12. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with
antidepressant drug treatment in depressive disorders: a systematic
review. Lancet 2003;361:653–61.
13. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry
1991;52(Suppl):28–34.
14. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational
criteria for treatment outcome of major depressive disorder. A
review of the current research literature. Arch Gen Psychiatry
1991;48:796–800.
15. Monroe SM, Harkness KL. Recurrence in major depression:
a conceptual analysis. Psychol Rev 2011;118:655–74.
16. Steinert C, Hofmann M, Kruse J, et al. The prospective long-term
course of adult depression in general practice and the community.
A systematic literature review. J Affect Disord 2014;152–154:65–75.
17. Eaton WW, Shao H, Nestadt G, et al. Population-based study of
first onset and chronicity in major depressive disorder. Arch Gen
Psychiatry 2008;65:513–20.
18. Hardeveld F, Spijker J, De Graaf R, et al. Recurrence of major
depressive disorder and its predictors in the general population:
results from the Netherlands Mental Health Survey and Incidence
Study (NEMESIS). Psychol Med 2013;43:39–48.
19. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and
predictors of recurrence of major depressive disorder in the adult
population. Acta Psychiatr Scand 2010;122:184–91.
20. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery
from major depressive disorder during 15 years of observational
follow-up. Am J Psychiatry 1999;156:1000–6.
21. Bhagwagar Z, Cowen PJ. ‘It’s not over when it’s over’: persistent
neurobiological abnormalities in recovered depressed patients.
Psychol Med 2008;38:307–13.
22. Bockting CL, Smid NH, Koeter MW, et al. Enduring effects of
Preventive Cognitive Therapy in adults remitted from recurrent
depression: A 10 year follow-up of a randomized controlled trial.
J Affect Disord 2015;185:188–94.
23. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during
the long-term course of unipolar major depressive disorder. Arch
Gen Psychiatry 2000;57:375–80.
24. Kaymaz N, van Os J, Loonen AJ, et al. Evidence that patients with
single versus recurrent depressive episodes are differentially
sensitive to treatment discontinuation: a meta-analysis of placebo-
controlled randomized trials. J Clin Psychiatr 2008;69:1423–36.
25. Bockting CL, ten Doesschate MC, Spijker J, et al. Continuation and
maintenance use of antidepressants in recurrent depression.
Psychother Psychosom 2008;77:17–26.
26. ten Doesschate MC, Bockting CL, Koeter MW, et al. Predictors of
nonadherence to continuation and maintenance antidepressant
medication in patients with remitted recurrent depression. J Clin
Psychiatry 2009;70:63–9.
27. ten Doesschate MC, Bockting CL, Schene AH. Adherence to
continuation and maintenance antidepressant use in recurrent
depression. J AffectDisord 2009;115:167–70.
28. Vittengl JR, Clark LA, Dunn TW, et al. Reducing relapse and
recurrence in unipolar depression: a comparative meta-analysis of
cognitive-behavioral therapy’s effects. J Consult Clin Psychol
2007;75:475–88.
29. Piet J, Hougaard E. The effect of mindfulness-based cognitive
therapy for prevention of relapse in recurrent major depressive
disorder: a systematic review and meta-analysis. Clin Psychol Rev
2011;31:1032–40.
30. Bockting CL, Schene AH, Spinhoven P, et al. Preventing relapse/
recurrence in recurrent depression with cognitive therapy:
a randomized controlled trial. J Consult Clin Psychol 2005;73:
647–57.
31. Bockting CL, Spinhoven P, Wouters LF, et al. Long-term effects of
preventive cognitive therapy in recurrent depression: a 5.5-year
follow-up study. J Clin Psychiatry 2009;70:1621–8.
32. Teasdale JD, Scott J, Moore RG, et al. How does cognitive therapy
prevent relapse in residual depression? Evidence from a controlled
trial. J Consult Clin Psychol 2001;69:347–57.
33. Teasdale JD, Segal ZV, Williams JM, et al. Prevention of relapse/
recurrence in major depression by mindfulness-based cognitive
therapy. J Consult Clin Psychol 2000;68:615–23.
34. Huijbers MJ, Spijker J, Donders AR, et al. Preventing relapse in
recurrent depression using mindfulness-based cognitive therapy,
antidepressant medication or the combination: trial design and
protocol of the MOMENT study. BMC Psychiatry 2012;12:125.
35. Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive
therapy to prevent relapse in recurrent depression. J Consult Clin
Psychol 2008;76:966–78.
36. Biesheuvel-Leliefeld KE, Kok GD, Bockting CL, et al. Effectiveness
of psychological interventions in preventing recurrence of
depressive disorder: Meta-analysis and meta-regression. J Affect
Disord 2014;174C:400–10.
37. Steinert C, Hofmann M, Kruse J, et al. Relapse rates after
psychotherapy for depression—stable long-term effects?
A meta-analysis. J Affect Disord 2014;168:107–18.
38. Bockting CL, Mocking RJ, Lok A, et al. Therapygenetics: the
5HTTLPR as a biomarker for response to psychological therapy?
MolPsychiatry 2013;18:744–5.
39. Kessing LV, Hansen MG, Andersen PK, et al. The predictive effect
of episodes on the risk of recurrence in depressive and bipolar
disorders—a life-long perspective. Acta Psychiatr Scand
2004;109:339–44.
40. Pettit JW, Lewinsohn PM, Joiner TE Jr. Propagation of major
depressive disorder: relationship between first episode symptoms
and recurrence. Psychiatry Res 2006;141:271–8.
41. Pettit JW, Hartley C, Lewinsohn PM, et al. Is liability to recurrent
major depressive disorder present before first episode onset in
adolescence or acquired after the initial episode? J Abnorm
Psychol 2013;122:353–8.
42. Bulloch A, Williams J, Lavorato D, et al. Recurrence of major
depressive episodes is strongly dependent on the number of
previous episodes. Depress Anxiety 2014;31:72–6.
43. Crona L, Bradvik L. Long-term course of severe depression: late
remission and recurrence May be found in a follow-up after 38–53
years. Ment Illn 2012;4:e17.
44. Monroe SM, Harkness KL. Is depression a chronic mental illness?
Psychol Med 2012;42:899–902.
14 Mocking RJT, et al. BMJ Open 2016;6:e009510. doi:10.1136/bmjopen-2015-009510
Open Access
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
45. Colman I, Naicker K, Zeng Y, et al. Predictors of long-term
prognosis of depression. CMAJ 2011;183:1969–76.
46. Merikangas KR, Zhang H, Avenevoli S, et al. Longitudinal trajectories
of depression and anxiety in a prospective community study: the
Zurich Cohort Study. Arch Gen Psychiatry 2003;60:993–1000.
47. Bockting CL, Spinhoven P, Koeter MW, et al. Prediction of
recurrence in recurrent depression and the influence of consecutive
episodes on vulnerability for depression: a 2-year prospective
study. J Clin Psychiatry 2006;67:747–55.
48. ten Doesschate MC, Bockting CL, Koeter MW, et al. Prediction of
recurrence in recurrent depression: a 5.5-year prospective study.
J Clin Psychiatry 2010;71:984–91.
49. Judd LL, Paulus, MJ, Schettler, PJ, et al. Does incomplete recovery
from first lifetime major depressive episode herald a chronic course
of illness? Am J Psychiatry 2000;157:1501–4.
50. Scher CD, Ingram RE, Segal ZV. Cognitive reactivity and
vulnerability: empirical evaluation of construct activation and
cognitive diatheses in unipolar depression. Clin Psychol Rev
2005;25:487–510.
51. Kendler KS, Thornton LM, Gardner CO. Stressful life events and
previous episodes in the etiology of major depression in women: an
evaluation of the “kindling” hypothesis. Am J Psychiatry
2000;157:1243–51.
52. Segal ZV, Williams JM, Teasdale JD, et al. A cognitive science
perspective on kindling and episode sensitization in recurrent
affective disorder. Psychol Med 1996;26:371–80.
53. Schumann G, Binder EB, Holte A, et al. Stratified medicine for
mental disorders. Eur Neuropsychopharmacol 2014;24:5–50.
54. Insel TR. The NIMH Research Domain Criteria (RDoC) Project:
precision medicine for psychiatry. Am J Psychiatry 2014;171:395–7.
55. Teasdale JD. Cognitive vulnerability to persistent depression. Cogn
Emotion 1988;2:247–74.
56. Segal ZV, Kennedy S, Gemar M, et al. Cognitive reactivity to sad
mood provocation and the prediction of depressive relapse. Arch
Gen Psychiatry 2006;63:749–55.
57. van Rijsbergen GD, Bockting CL, Burger H, et al. Mood reactivity
rather than cognitive reactivity is predictive of depressive relapse:
a randomized study with 5.5-year follow-up. J Consult Clin Psychol
2013;81:508–17.
58. Michalak J, Hölz A, Teismann T. Rumination as a predictor of
relapse in mindfulness-based cognitive therapy for depression.
Psychol Psychother 2011;84:230–6.
59. Whitton AE, Treadway MT, Pizzagalli DA. Reward processing
dysfunction in major depression, bipolar disorder and
schizophrenia. Curr Opin Psychiatry 2015;28:7–12.
60. Eshel N, Roiser JP. Reward and punishment processing in
depression. Biol Psychiatry 2010;68:118–24.
61. Pizzagalli DA. Depression, stress, and anhedonia: toward a
synthesis and integrated model. Annu Rev Clin Psychol
2014;10:393–423.
62. Treadway MT, Zald DH. Reconsidering anhedonia in depression:
lessons from translational neuroscience. Neurosci Biobehav Rev
2011;35:537–55.
63. Fredrickson BL. The role of positive emotions in positive
psychology. The broaden-and-build theory of positive emotions.
Am Psychol 2001;56:218–26.
64. Mathews A, MacLeod C. Cognitive approaches to emotion and
emotional disorders. Annu Rev Psychol 1994;45:25–50.
65. De Raedt R, Koster EH. Understanding vulnerability for depression
from a cognitive neuroscience perspective: a reappraisal of
attentional factors and a new conceptual framework. Cogn Affect
Behav Neurosci 2010;10:50–70.
66. Leyman L, De Raedt R, Schacht R, et al. Attentional biases for
angry faces in unipolar depression. Psychol Med 2007;37:393–402.
67. Goeleven E, De Raedt R, Baert S, et al. Deficient inhibition of
emotional information in depression. J Affect Disord 2006;93:149–57.
68. Joormann J, Gotlib IH. Selective attention to emotional faces following
recovery from depression. J Abnorm Psychol 2007;116:80–5.
69. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take
so long to work? A cognitive neuropsychological model of
antidepressant drug action. Br J Psychiatry 2009;195:102–8.
70. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus
medication for depression: treatment outcomes and neural
mechanisms. Nat Rev Neurosci 2008;9:788–96.
71. Harmer CJ, O’Sullivan U, Favaron E, et al. Effect of acute
antidepressant administration on negative affective bias in
depressed patients. Am J Psychiatry 2009;166:1178–84.
72. Pizzagalli DA, Peccoralo LA, Davidson RJ, et al. Resting anterior
cingulate activity and abnormal responses to errors in subjects with
elevated depressive symptoms: a 128-channel EEG study.
Hum Brain Mapp 2006;27:185–201.
73. Nolen-Hoeksema S. The role of rumination in depressive disorders
and mixed anxiety/depressive symptoms. J Abnorm Psychol
2000;109:504–11.
74. Ingram RE. Origins of cognitive vulnerability to depression. Cognit
Ther Res 2003;27:77–88.
75. Nejad AB, Fossati P, Lemogne C. Self-referential processing,
rumination, and cortical midline structures in major depression.
Front Hum Neurosci 2013;7:666.
76. Lau MA, Segal ZV, Williams JM. Teasdale’s differential activation
hypothesis: implications for mechanisms of depressive relapse and
suicidal behaviour. Behav Res Ther 2004;42:1001–17.
77. Bouhuys AL, Geerts E, Gordijn MC. Depressed patients’
perceptions of facial emotions in depressed and remitted states are
associated with relapse: a longitudinal study. J Nerv Ment Dis
1999;187:595–602.
78. Nandrino JL, Dodin V, Martin P, et al. Emotional information
processing in first and recurrent major depressive episodes.
J Psychiatr Res 2004;38:475–84.
79. Leppanen JM. Emotional information processing in mood disorders:
a review of behavioral and neuroimaging findings. Curr Opin
Psychiatry 2006;19:34–9.
80. Elgersma HJ, Glashouwer KA, Bockting CL, et al. Hidden scars in
depression? Implicit and explicit self-associations following recurrent
depressive episodes. J Abnorm Psychol 2013;122:951–60.
81. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion
perception II: implications for major psychiatric disorders. Biol
Psychiatry 2003;54:515–28.
82. Phillips ML, Ladouceur CD, Drevets WC. A neural model of
voluntary and automatic emotion regulation: implications for
understanding the pathophysiology and neurodevelopment of
bipolar disorder. Mol Psychiatry 2008;13:829, 33–57.
83. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in
depression: towards development of brain-based algorithms for
diagnosis and optimised treatment. Br Med Bull 2003;65:
193–207.
84. Pizzagalli DA. Frontocingulate dysfunction in depression: toward
biomarkers of treatment response. Neuropsychopharmacology
2011;36:183–206.
85. Surguladze S, Brammer MJ, Keedwell P, et al. A differential pattern
of neural response toward sad versus happy facial expressions in
major depressive disorder. Biol Psychiatry 2005;57:201–9.
86. Ruhé HG, Booij J, Veltman DJ, et al. Successful pharmacologic
treatment of major depressive disorder attenuates amygdala
activation to negative facial expressions: a functional magnetic
resonance imaging study. J Clin Psychiatry 2012;73:451–9.
87. Groenewold NA, Opmeer EM, de Jonge P, et al. Emotional valence
modulates brain functional abnormalities in depression: evidence
from a meta-analysis of fMRI studies. Neurosci Biobehav Rev
2013;37:152–63.
88. Rive MM, van Rooijen G, Veltman DJ, et al. Neural correlates of
dysfunctional emotion regulation in major depressive disorder.
A systematic review of neuroimaging studies. Neurosci Biobehav
Rev 2013;37(10 Pt 2):2529–53.
89. Frodl TS, Koutsouleris N, Bottlender R, et al. Depression-related
variation in brain morphology over 3 years: effects of stress? Arch
Gen Psychiatry 2008;65:1156–65.
90. Marchetti I, Koster EH, Sonuga-Barke EJ, et al. The default mode
network and recurrent depression: a neurobiological model of
cognitive risk factors. Neuropsychol Rev 2012;22:229–51.
91. Chai XJ, Castanon AN, Ongur D, et al. Anticorrelations in resting
state networks without global signal regression. NeuroImage
2012;59:1420–8.
92. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity
observed with functional magnetic resonance imaging. Nat Rev
Neurosci 2007;8:700–11.
93. Fox MD, Snyder AZ, Vincent JL, et al. The human brain is
intrinsically organized into dynamic, anticorrelated functional
networks. Proc Natl Acad Sci USA 2005;102:9673–8.
94. Fransson P. Spontaneous low-frequency BOLD signal fluctuations:
An fMRI investigation of the resting-state default mode of brain
function hypothesis. Hum Brain Mapp 2005;26:15–29.
95. Anticevic A, Cole MW, Murray JD, et al. The role of default network
deactivation in cognition and disease. Trends Cogn Sci (Regul Ed)
2012;16:584–92.
96. Kaiser RH, Andrews-Hanna JR, Wager TD, et al. Large-Scale
Network Dysfunction in Major Depressive Disorder: A
Meta-analysis of Resting-State Functional Connectivity. JAMA
Psychiatry 2015;72:603–11.
97. Sheline YI, Price JL, Yan Z, et al. Resting-state functional MRI in
depression unmasks increased connectivity between networks via
the dorsal nexus. Proc Natl Acad Sci USA 2010;107:11020–5.
Mocking RJT, et al. BMJ Open 2016;6:e009510. doi:10.1136/bmjopen-2015-009510 15
Open Access
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
98. Greicius MD, Flores BH, Menon V, et al. Resting-state functional
connectivity in major depression: abnormally increased
contributions from subgenual cingulate cortex and thalamus.
Biol Psychiatry 2007;62:429–37.
99. Zhou Y, Yu C, Zheng H, et al. Increased neural resources
recruitment in the intrinsic organization in major depression.
J Affect Disord 2010;121:220–30.
100. Grimm S, Boesiger P, Beck J, et al. Altered negative BOLD
responses in the default-mode network during emotion processing in
depressed subjects. Neuropsychopharmacology 2009;34:932–43.
101. Raichle ME, Gusnard DA. Intrinsic brain activity sets the stage for
expression of motivated behavior. J Comp Neurol 2005;493:167-76.
102. Belleau EL, Taubitz LE, Larson CL. Imbalance of default mode and
regulatory networks during externally focused processing in
depression. Soc Cogn Affect Neurosci 2015;10:744–51.
103. Farb NA, Anderson AK, Bloch RT, et al. Mood-linked responses in
medial prefrontal cortex predict relapse in patients with recurrent
unipolar depression. Biol Psychiatry 2011;70:366–72.
104. Zhu X, Wang X, Xiao J, et al. Evidence of a dissociation pattern in
resting-state default mode network connectivity in first-episode,
treatment-naive major depression patients. Biol Psychiatry
2012;71:611–7.
105. Berman MG, Peltier S, Nee DE, et al. Depression, rumination and
the default network. Soc Cogn Affect Neurosci 2011;6:548–55.
106. Hamilton JP, Furman DJ, Chang C, et al. Default-mode and
task-positive network activity in major depressive disorder:
implications for adaptive and maladaptive rumination. Biol
Psychiatry 2011;70:327–33.
107. Pechtel P, Dutra SJ, Goetz EL, et al. Blunted reward responsiveness
in remitted depression. J Psychiatr Res 2013;47:1864–9.
108. Kumar P, Waiter G, Ahearn T, et al. Abnormal temporal difference
reward-learning signals in major depression. Brain 2008;131(Pt
8):2084–93.
109. Morgan JK, Olino TM, McMakin DL, et al. Neural response to
reward as a predictor of increases in depressive symptoms in
adolescence. Neurobiol Dis 2013;52:66–74.
110. Hall GB, Milne AM, Macqueen GM. An fMRI study of reward
circuitry in patients with minimal or extensive history of major
depression. Eur Arch Psychiatry Clin Neurosci 2014;264:187–98.
111. Ramel W, Goldin PR, Eyler LT, et al. Amygdala reactivity and
mood-congruent memory in individuals at risk for depressive
relapse. Biol Psychiatry 2007;61:231–9.
112. Hooley JM, Gruber SA, Parker HA, et al. Cortico-limbic response to
personally challenging emotional stimuli after complete recovery
from depression. Psychiatry Res 2009;172:83–91.
113. Hooley JM, Gruber SA, Scott LA, et al. Activation in dorsolateral
prefrontal cortex in response to maternal criticism and praise in
recovered depressed and healthy control participants. Biol
Psychiatry 2005;57:809–12.
114. Levesque J, Eugene F, Joanette Y, et al. Neural circuitry underlying
voluntary suppression of sadness. Biol Psychiatry 2003;53:502–10.
115. van Tol MJ, van der Wee NJ, van den Heuvel OA, et al. Regional
brain volume in depression and anxiety disorders. Arch Gen
Psychiatry 2010;67:1002–11.
116. Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal and
amygdala changes in patients with major depressive disorder and
healthy controls during a 1-year follow-up. J Clin Psychiatry
2004;65:492–9.
117. Kronmuller KT, Pantel J, Kohler S, et al. Hippocampal volume and
2-year outcome in depression. Br J Psychiatry 2008;192:472–3.
118. Frodl T, Jager M, Born C, et al. Anterior cingulate cortex does not
differ between patients with major depression and healthy controls,
but relatively large anterior cingulate cortex predicts a good clinical
course. Psychiatry Res 2008;163:76–83.
119. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal
activation: a quantitative summary of four decades of research.
Psychosom Med 2011;73:114–26.
120. Lok A, Mocking RJ, Ruhé HG, et al. Longitudinal hypothalamic-
pituitary-adrenal axis trait and state effects in recurrent depression.
Psychoneuroendocrinology 2012;37:892–902.
121. Assies J, Visser I, Nicolson NA, et al. Elevated salivary
dehydroepiandrosterone-sulfate but normal cortisol levels in
medicated depressed patients: preliminary findings. Psychiatry Res
2004;128:117–22.
122. Appelhof BC, Huyser J, Verweij M, et al. Glucocorticoids and
relapse of major depression (dexamethasone/
corticotropin-releasing hormone test in relation to relapse of major
depression). BiolPsychiatry 2006;59:696–701.
123. Aubry JM, Gervasoni N, Osiek C, et al. The DEX/CRH
neuroendocrine test and the prediction of depressive relapse in
remitted depressed outpatients. J Psychiatr Res 2007;41:290–4.
124. Bockting CL, Lok A, Visser I, et al. Lower cortisol levels predict
recurrence in remitted patients with recurrent depression: a 5.5
year prospective study. Psychiatry Res 2012;200:281–7.
125. Hardeveld F, Spijker J, Vreeburg SA, et al. Increased cortisol
awakening response was associated with time to recurrence of
major depressive disorder. Psychoneuroendocrinology
2014;50:62–71.
126. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness,
hippocampal function, and hippocampal volume in major
depression. Proc Natl Acad Sci U S A 2003;100:1387–92.
127. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry
2003;54:200–7.
128. Malhi GS, Parker GB, Greenwood J. Structural and functional
models of depression: from sub-types to substrates. Acta Psychiatr
Scand 2005;111:94–105.
129. Urry HL, van Reekum CM, Johnstone T, et al. Amygdala and
ventromedial prefrontal cortex are inversely coupled during
regulation of negative affect and predict the diurnal pattern of
cortisol secretion among older adults. J Neurosci
2006;26:4415–25.
130. Mocking RJ, Ruhé HG, Assies J, et al. Relationship between the
hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in
recurrent depression. Psychoneuroendocrinology
2013;38:1607–17.
131. Mocking RJT, Assies J, Bot M, et al. Biological effects of add-on
eicosapentaenoic acid supplementation in diabetes mellitus and
co-morbid depression: a randomized controlled trial. PLoS ONE
2012;7:e49431.
132. Martinez M, Mougan I. Fatty acid composition of human brain
phospholipids during normal development. J Neurochem
1998;71:2528–33.
133. Piomelli D, Astarita G, Rapaka R. A neuroscientist’s guide to
lipidomics. Nat Rev Neurosci 2007;8:743–54.
134. Rao JS, Ertley RN, Lee HJ, et al. n-3 polyunsaturated fatty acid
deprivation in rats decreases frontal cortex BDNF via a p38
MAPK-dependent mechanism. Mol Psychiatry 2007;12:36–46.
135. Martinowich K, Lu B. Interaction between BDNF and serotonin: role
in mood disorders. Neuropsychopharmacology 2008;33:73–83.
136. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites
in brain function and disease. Nat Rev Neurosci 2014;15:771–85.
137. Assies J, Pouwer F, Lok A, et al. Plasma and erythrocyte fatty acid
patterns in patients with recurrent depression: a matched
case-control study. PLoS ONE 2010;5:e10635.
138. Mocking RJ, Assies J, Koeter MW, et al. Bimodal distribution of
fatty acids in recurrent major depressive disorder. Biol Psychiatry
2012;71:e3–5.
139. Mocking RJ, Assies J, Lok A, et al. Statistical methodological
issues in handling of fatty acid data: percentage or concentration,
imputation and indices. Lipids 2012;47:541–7.
140. Mocking RJ, Lok A, Assies J, et al. Ala54Thr fatty acid-binding
protein 2 (FABP2) polymorphism in recurrent depression:
associations with fatty acid concentrations and waist circumference.
PLoS ONE 2013;8:e82980.
141. McNamara RK. Deciphering the role of docosahexaenoic acid in
brain maturation and pathology with magnetic resonance imaging.
Prostaglandins Leukot Essent Fatty Acids 2013;88:33–42.
142. Ende G, Demirakca T, Tost H. The biochemistry of dysfunctional
emotions: proton MR spectroscopic findings in major depressive
disorder. Prog Brain Res 2006;156:481–501.
143. Muller N, Schwarz MJ. The immune-mediated alteration of
serotonin and glutamate: towards an integrated view of depression.
Mol Psychiatry 2007;12:988–1000.
144. Walter M, Henning A, Grimm S, et al. The relationship between
aberrant neuronal activation in the pregenual anterior cingulate,
altered glutamatergic metabolism, and anhedonia in major
depression. Arch Gen Psychiatry 2009;66:478–86.
145. Northoff G, Walter M, Schulte RF, et al. GABA concentrations in
the human anterior cingulate cortex predict negative BOLD
responses in fMRI. Nat Neurosci 2007;10:1515–7.
146. Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance
spectroscopy findings in major depressive disorder: a
meta-analysis. Psychiatry Res 2006;147:1–25.
147. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of
glutamate-related abnormalities in mood disorders. Biol Psychiatry
2010;68:785–94.
148. Hasler G, Neumeister A, van der Veen JW, et al. Normal prefrontal
gamma-aminobutyric acid levels in remitted depressed subjects
determined by proton magnetic resonance spectroscopy. Biol
Psychiatry 2005;58:969–73.
149. Capizzano AA, Jorge RE, Acion LC, et al. In vivo proton magnetic
resonance spectroscopy in patients with mood disorders: a
16 Mocking RJT, et al. BMJ Open 2016;6:e009510. doi:10.1136/bmjopen-2015-009510
Open Access
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
technically oriented review. J Magn Reson Imaging
2007;26:1378–89.
150. First MB, Gibbon M, Spitzer RL, et al. User Guide for the
Structured Clinical Interview for DSM-IV Axis-1 Disorders.
Washington DC: American Psychiatric Association, 1996.
151. Hamilton M. A rating scale for depression. J Neurol Neurosurg
Psychiatr 1960;23:56–62.
152. Bockting CL, Spinhoven P, Koeter MW, et al. Differential predictors
of response to preventive cognitive therapy in recurrent depression:
a 2-year prospective study. Psychother Psychosom
2006;75:229–36.
153. First MB, Pincus HA. The DSM-IV Text Revision: rationale and
potential impact on clinical practice. Psychiatr Serv
2002;53:288–92.
154. Posner MI, Snyder CR, Davidson BJ. Attention and the detection of
signals. J Exp Psychol 1980;109:160–74.
155. Mocking RJ, Patrick Pflanz C, Pringle A, et al. Effects of short-term
varenicline administration on emotional and cognitive processing in
healthy, non-smoking adults: a randomized, double-blind, study.
Neuropsychopharmacology 2013;38:476–84.
156. Chambers R, Lo BCY, Allen NB. The impact of intensive
mindfulness training on attentional control, cognitive style, and
affect. Cognit Ther Res 2008;32:303–22.
157. De Lissnyder E, Koster EH, De Raedt R. Emotional interference in
working memory is related to rumination. Cognit Ther Res
2012;36:348–57.
158. Schmand B, Bakker D, Saan R, et al. [The Dutch Reading Test for
Adults: a measure of premorbid intelligence level]. Tijdschr
Gerontol Geriatr 1991;22:15–9.
159. Myin-Germeys I, Oorschot M, Collip D, et al. Experience sampling
research in psychopathology: opening the black box of daily life.
Psychol Med 2009;39:1533–47.
160. Shiffman S, Stone AA, Hufford MR. Ecological momentary
assessment. Annu Rev Clin Psychol 2008;4:1–32.
161. Wichers M, Peeters F, Geschwind N, et al. Unveiling patterns of
affective responses in daily life may improve outcome prediction in
depression: a momentary assessment study. J Affect Disord
2010;124:191–5.
162. Csikszentmihalyi M, Larson R. Validity and reliability of the
Experience-Sampling Method. J Nerv Ment Dis 1987;175:526–36.
163. Crawford JR, Henry JD. The positive and negative affect schedule
(PANAS): construct validity, measurement properties and
normative data in a large non-clinical sample. Br J Clin Psychol
2004;43(Pt 3):245–65.
164. Schulte RF, Lange T, Beck J, et al. Improved two-dimensional
J-resolved spectroscopy. NMR Biomed 2006;19:264–70.
165. Waddell KW, Avison MJ, Joers JM, et al. A practical guide to robust
detection of GABA in human brain by J-difference spectroscopy at
3 T using a standard volume coil. Magn Reson Imaging
2007;25:1032–8.
166. van Loon A M, Knapen T, Scholte HS, et al. GABA shapes the
dynamics of bistable perception. Curr Biol 2013;23:823–7.
167. Taylor WD, Hsu E, Krishnan KR, et al. Diffusion tensor imaging:
background, potential, and utility in psychiatric research. Biol
Psychiatry 2004;55:201–7.
168. Vanderhasselt MA, Baeken C, Van Schuerbeek P, et al. How
brooding minds inhibit negative material: an event-related fMRI
study. Brain Cogn 2013;81:352–9.
169. Lok A, Bockting CL, Koeter MW, et al. Interaction between the
MTHFR C677T polymorphism and traumatic childhood events
predicts depression. Transl Psychiatry 2013;3:e288.
170. Lok A, Mocking RJ, Assies J, et al. The one-carbon-cycle and
methylenetetrahydrofolate reductase (MTHFR) C677T
polymorphism in recurrent major depressive disorder; influence of
antidepressant use and depressive state? J Affect Disord
2014;166:115–23.
171. Naviaux RK. Metabolic features of the cell danger response.
Mitochondrion 2014;16:7–17.
172. Kirschbaum C, Hellhammer DH. Salivary cortisol in
psychoneuroendocrine research: recent developments and
applications. Psychoneuroendocrinology 1994;19:313–33.
173. Whetzel CA, Klein LC. Measuring DHEA-S in saliva: time of day
differences and positive correlations between two different types of
collection methods. BMC Res Notes 2010;3:204.
174. Beevers CG, Strong DR, Meyer B, et al. Efficiently assessing
negative cognition in depression: an item response theory analysis
of the Dysfunctional Attitude Scale. Psychol Assess
2007;19:199–209.
175. de Graaf LE, Roelofs J, Huibers MJ. Measuring dysfunctional
attitudes in the general population: the dysfunctional attitude Scale
(form A) revised. Cognit Ther Res 2009;33:345–55.
176. Shahand S, Santcroos M, van Kampen AHC, et al. A Grid-Enabled
Gateway for Biomedical Data Analysis. J Grid Comput
2012;10:725–42.
177. Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle
introduction to imputation of missing values. J Clin Epidemiol
2006;59:1087–91.
178. Vaden KI Jr, Gebregziabher M, Kuchinsky SE, et al. Multiple
imputation of missing fMRI data in whole brain analysis.
NeuroImage 2012;60:1843–55.
179. Peeters F, Nicolson NA, Berkhof J, et al. Effects of daily events on
mood states in major depressive disorder. J Abnorm Psychol
2003;112:203–11.
180. Delespaul PAEGe. Assessing Schizophrenia in Daily Life. The
Experience Sampling Method. Maastricht: Maastricht University
Press, 1995.
181. Ashburner J, Friston KJ. Voxel-based morphometry--the methods.
NeuroImage 2000;11(6 Pt 1):805–21.
182. Ridgway GR, Henley SM, Rohrer JD, et al. Ten simple rules for
reporting voxel-based morphometry studies. Neuroimage
2008;40:1429–35.
183. Bach M, Laun FB, Leemans A, et al. Methodological considerations
on tract-based spatial statistics (TBSS). Neuroimage
2014;100:358–69.
184. Maninger N, Wolkowitz OM, Reus VI, et al. Neurobiological and
neuropsychiatric effects of dehydroepiandrosterone (DHEA) and
DHEA sulfate (DHEAS). Front Neuroendocrinol 2009;30:65–91.
185. Mumford JA, Nichols TE. Power calculation for group fMRI studies
accounting for arbitrary design and temporal autocorrelation.
NeuroImage 2008;39:261–8.
186. Hayasaka S, Peiffer AM, Hugenschmidt CE, et al. Power and
sample size calculation for neuroimaging studies by non-central
random field theory. NeuroImage 2007;37:721–30.
187. Murphy K, Bodurka J, Bandettini PA. How long to scan? The
relationship between fMRI temporal signal to noise ratio and
necessary scan duration. Neuroimage 2007;34:565–74.
188. Siegle GJ, Thompson WK, Collier A, et al. Toward clinically useful
neuroimaging in depression treatment: prognostic utility of
subgenual cingulate activity for determining depression outcome in
cognitive therapy across studies, scanners, and patient
characteristics. Arch Gen Psychiatry 2012;69:913–24.
189. Gueorguieva R, Krystal JH. Move over ANOVA: progress in
analyzing repeated-measures data and its reflection in papers
published in the Archives of General Psychiatry. Arch Gen
Psychiatry 2004;61:310–7.
190. Rosenbaum PR, Rubin DB. The Central Role of the Propensity
Score in Observational Studies for Causal Effects. Biometrika
1983;70:41–55.
191. Borsboom D, Cramer AO. Network analysis: an integrative
approach to the structure of psychopathology. Annu Rev Clin
Psychol 2013;9:91–121.
192. van Borkulo CD, Borsboom D, Epskamp S, et al. A new method for
constructing networks from binary data. Sci Rep 2014;4:5918.
193. Orrù G, Pettersson-Yeo W, Marquand AF, et al. Using Support
Vector Machine to identify imaging biomarkers of neurological and
psychiatric disease: a critical review. Neurosci Biobehav Rev
2012;36:1140–52.
194. Epstein RM, Duberstein PR, Feldman MD, et al. “I didn’t know what
was wrong:” how people with undiagnosed depression recognize,
name and explain their distress. J Gen Intern Med 2010;25:954–61.
195. Guo Q, Parlar M, Truong W, et al. The reporting of observational
clinical functional magnetic resonance imaging studies: a
systematic review. PLoS ONE 2014;9:e94412.
196. Connell L, MacDonald R, McBride T, et al. Observational studies:
getting clear about transparency. PLoS Med 2014;11:e1001711.
197. von Elm E, Altman DG, Egger M, et al. Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. BMJ
2007;335:806–8.
198. Hrynaszkiewicz I, Norton ML, Vickers AJ, et al. Preparing raw
clinical data for publication: guidance for journal editors, authors,
and peer reviewers. BMJ 2010;340:c181.
199. Holsboer F, Bender W, Benkert O, et al. Diagnostic value of
dexamethasone suppression test in depression. Lancet
1980;2:706.
200. van der Kolk AG, Hendrikse J, Zwanenburg JJ, et al. Clinical
applications of 7 T MRI in the brain. Eur J Radiol 2013;82:708–18.
201. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of
major depressive disorder. Am J Psychiatry 2000;157:229–33.
202. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral
weight-loss intervention in persons with serious mental illness.
N Engl J Med 2013;368:1594–602.
Mocking RJT, et al. BMJ Open 2016;6:e009510. doi:10.1136/bmjopen-2015-009510 17
Open Access
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
study
longitudinal DELTA-neuroimaging cohort
major depressive disorder: protocol for the 
Vulnerability for new episodes in recurrent
Bockting, Catherine J Harmer, Aart H Schene and Henricus G Ruhé
Vaz, Marieke Wichers, Jan P van Straalen, Rudi de Raedt, Claudi L H
Michelle N Servaas, Johanna Assies, Maarten W J Koeter, Frédéric M 
Roel J T Mocking, Caroline A Figueroa, Maria M Rive, Hanneke Geugies,
doi: 10.1136/bmjopen-2015-009510
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/3/e009510
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/3/e009510
This article cites 199 articles, 16 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (85)Radiology and imaging
 (221)Nutrition and metabolism
 (476)Mental health
 (1529)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
